AVEO Oncology Highlights Key Research at ASCO 2025
AVEO Oncology, operating under LG Chem, is making waves in the biopharmaceutical industry with its recent announcement of three noteworthy abstracts set to be presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting. This prestigious event will take place from May 30 to June 3, 2025, in Chicago, IL, and serves as a platform for sharing the latest insights and advancements in cancer research and treatments.
The first abstract focuses on the efficacy of
tivozanib (Tivo) as a treatment for patients with metastatic renal cell carcinoma (mRCC). The study, titled
Efficacy of second-line (2L) treatment with tivozanib (Tivo) as monotherapy or with nivolumab (Nivo) in patients previously treated with immune checkpoint inhibitors, will be led by Dr. Alexander Chehrazi-Raffle from City of Hope Cancer Center. This research targets a significant patient population that has experienced limited treatment options, presenting a promising avenue for better management of renal cancer. The presentation will take place on June 2, 2025, during the Genitourinary Cancer session.
Following this, AVEO will present findings from the
FIERCE-HN study, which investigates
ficlatuzumab in combination with cetuximab for patients with recurrent or metastatic HPV-negative head and neck squamous cell carcinoma. Dr. Julie E. Bauman from the George Washington University Cancer Center will lead this pivotal trial which aims to offer new hope for patients battling this difficult-to-treat cancer type. This presentation will also occur on June 2, emphasizing the need for innovative strategies in head and neck oncology.
Lastly, AVEO introduces research on
AV-380, an anti-GDF15 monoclonal antibody in a Phase 1b dose escalation study. This study aims to explore the combination of AV-380 with standard-of-care therapy for cancer patients experiencing cachexia. Dr. Eric Roeland from Oregon Health Science University will present this study, which highlights AVEO's commitment to addressing under-researched areas in cancer treatment, particularly the debilitating effects of cachexia—a common condition in advanced cancer patients.
These presentations underscore AVEO's ongoing dedication to developing effective treatments that significantly enhance the quality of life for cancer patients. Since becoming a wholly owned subsidiary of LG Chem Life Sciences USA, AVEO has continued to focus on oncology solutions, including the marketed product FOTIVDA® (tivozanib), which is used for relapsed or refractory advanced renal cell carcinoma.
AVEO Oncology operates with the mission to bring innovative solutions to unmet medical needs in oncology, and as shown at ASCO 2025, is at the forefront of research that expands treatment options and improves patient outcomes.
For more information about AVEO and its developments, please visit
LG Chem's website. Their continued investment in cancer research demonstrates a significant commitment to battling this complex and challenging disease.
In conclusion, the ASCO 2025 meeting will provide a valuable platform for AVEO to present its latest research, contributing to the ongoing dialogue in the oncology community and fostering collaborations toward improved cancer care.